00719 SHANDONG XINHUA
- 5.660
- +0.030+0.53%
SHANDONG XINHUA News
Xinhua Pharmaceutical (000756.SZ): R&D investment reached 406 million yuan in 2023
Gelonghui, May 9丨Xinhua Pharmaceutical (000756.SZ) said on the investor interactive platform that the company has continued to increase R&D investment in recent years, reaching 406 million yuan in R&D in 2023. The company carries out research and development work on cardiovascular, antipyretic and analgesic, digestive, anti-metabolic, neurological, narcotic drugs, etc., including innovative drugs and generic drugs. There are more than 100 drugs entering the R&D pipeline. R&D strategies include: first, combining the characteristics and advantages of the enterprise's entire industry chain, starting from technical quality advantages, cost advantages, supporting advantages, etc., to accelerate R&D and listing of key products; second
Xinhua Pharmaceutical (000756.SZ): Using synthetic biology technology to produce products including the dopamine series
Gelonghui, May 9丨An investor asked Xinhua Pharmaceuticals (000756.SZ) on the investor interactive platform, “What products does your company produce using synthetic biology technology?” The company replied that the company uses synthetic biology technology to produce products including the dopamine series.
Xinhua Pharmaceutical (000756.SZ): The company is an important global supplier of antipyretic and analgesic drugs
Gelonghui, May 7 | Xinhua Pharmaceutical (000756.SZ) said on the investor interactive platform that the company is an important global supplier of antipyretic and analgesic drugs and is an important domestic manufacturer of cardiovascular, anti-infective and central nervous system drugs. The company has core competitiveness such as outstanding scale advantages, obvious supporting advantages, and leading technical and economic indicators, and has a high position and influence in the domestic pharmaceutical industry. The company is one of the top 100 enterprises in the national pharmaceutical industry, the top five exporters of APIs, and the top ten pharmaceutical exporters. Has aspirin, ibuprofen, levodopa, ethoxyphenyllamine, triphenyldiamidine, marlinzin, and pyrimidine
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Featured announcements | CNOOC's net profit for the first quarter was nearly 40 billion yuan; China Aluminum's net profit for the first quarter increased 23.01% year-on-year
ZTE's net profit for the first quarter increased by 3.74% year on year; Times Electric's net profit for the first quarter increased by 30.44% year on year.
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) announced first-quarter results, net profit of 142 million yuan, a year-on-year decrease of 6.41%
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) announced results for the first quarter of 2024. The group achieved operating income of 2,475 billion yuan (RMB, same below) during the period, a year-on-year decrease of 6.25%; net profit to mother was 142 million yuan, a year-on-year decrease of 6.41%; and basic earnings per share were 0.21 yuan.
山東新華製藥股份：2024年第一季度未經審核的業績
山東新華製藥股份：2023年年報
Xinhua Pharmaceutical (000756.SZ): Pharmaceutical exports to the US and the US account for about 10% of the company's total sales
Gelonghui, April 17 | Xinhua Pharmaceutical (000756.SZ) said on the investor interactive platform that the company's pharmaceutical exports to the US, including the US, account for about 10% of the company's total sales.
Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation
Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) said cefaclor capsules, a drug of its unit Shandong Zibo Xinda Pharmaceutical, passed the quality and efficacy evaluation of China's National Medi
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) plans to hold a board meeting on April 25 to approve quarterly results
Gelonghui, April 11, 丨 Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) announced that the company will hold a board meeting at 9:30 a.m. on April 25, 2024 (Thursday) in the company conference room No. 1, Lutai Avenue, High-tech Zone, Zibo City, Shandong Province. The contents of the meeting are as follows: 1. Review and approve the unaudited performance of the company and its subsidiaries for the three months ended March 31, 2024; and 2. Any other matters, if applicable.
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Express News | Xinhua Pharmaceuticals: Cefaclor capsules passed the consistent evaluation of generic drug quality and efficacy
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK): Wholly-owned subsidiary cefaclor capsules passed generic drug consistency evaluation
Gelonghui, April 10 | Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) announced that recently, Shandong Zibo Xinda Pharmaceutical Co., Ltd. (hereinafter referred to as “Xinda Pharmaceutical”), a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” for cefaclor capsules (hereinafter referred to as “this product”) approved and issued by the State Drug Administration. The product passed the consistent evaluation of the quality and efficacy of generic drugs.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Selected announcements | China's non-ferrous mining industry plans to sell up to 163 million shares at a discount of about 13.54%; Longyuan Electric Power's power generation will increase by about 10% during the year
China's net profit for the first quarter was 2,308 billion yuan, up 0.33% year on year; Qiutai Technology sold about 368.39 million mobile phone camera modules in March, up 31.8% from month to month, down 1.7% year on year.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK): Obtained approval notice for supplemental application for peramivir injectable drugs
Gelonghui, April 8, 丨 Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) issued an announcement. Recently, the company received the “Drug Supplement Application Approval Notice” for paramivir injection (15ml: 0.15g) approved by the State Drug Administration, and the transfer application of the product's marketing license holder was approved.
Featured announcements | BYD's automobile sales in March increased 46.06% year on year; COSCO Haineng's profit more than doubled last year
Ideal Auto delivered 28,984 new cars in March, up 39.2% year on year; NIO delivered 11,866 cars in March, up 14.3% year on year; Xiaopeng Motor delivered 9,026 new cars in March, up 99% month on month, up 29% year on year.
Analysis
Price Target
No Data
